In-silico analysis on potential anti-SARS-CoV-۲ protease agents by structure-based docking and cheminformatics

سال انتشار: 1399
نوع سند: مقاله ژورنالی
زبان: انگلیسی
مشاهده: 61

فایل این مقاله در 15 صفحه با فرمت PDF قابل دریافت می باشد

استخراج به نرم افزارهای پژوهشی:

لینک ثابت به این مقاله:

شناسه ملی سند علمی:

JR_PRJMS-24-2_002

تاریخ نمایه سازی: 30 فروردین 1404

چکیده مقاله:

Trying to treat COVID-۱۹ patients has caused serious problems for the scientists. There are many routinely used drugs in clinical settings without definite effects, and more studies should be done so as to reach a successful treatment for COVID-۱۹. Our aim is to evaluate four suggested chemicals using virtual analysis tools based on the drug-screening approach and application of cheminformatics, pharmacotoxicology and docking. Four repurposed drugs: rizatriptan, dasabuvir, pravastatin, and empagliflozin are used in the study. The ۳D structure of COVID-۱۹ Main Protease (M Pro) was obtained from protein data bank (PDB) with PDB code: ۶LU۷, as the target of binding site screening. Besides, cheminformatics, pharmacotoxicology and human proteins targets for each drug was evaluated using SwissADME interface, SwissTarget Prediction web server, toxicity estimation software tool (T.E.S.T) and Toxtree-v۳.۱.۰.۱۸۵۱ offline software. The docking scores (DOS) were -۱۳۹.۳۹۹, -۱۲۵.۷۰۷, -۱۰۲.۱۸۳ and -۹۹.۶۶۴۲ for dasabuvir, rizatriptan, empagliflozin and pravastatin, respectively. In addition, the quantitative structure-activity relationship (QSAR) and pharmacotoxicologic evaluations show dasabuvir has more acceptable results than the others. Human protein target-exploration show that rizatriptan interacts with G protein-coupled receptor and kinase enzymes, pravastatin targets the ۳-hydroxy-۳-methylglutaryl coenzyme A (HMG-CoA) reductase, while empagliflozin interacts with sodium/glucose cotransporters (SLC). But, dasabuvir targets human protein with too low scores. Virtual screening applied to four potential anti-COVID-۱۹ drugs shows that dasabuvir may be a safer and efficient agent, regarding pharmacotoxicology and therapeutic purposes. However, virtually screened agent/s should be evaluated by experimental models for ultimate confirmation.

نویسندگان

تقی طریحی

Tarbiat Modares Univ

عبدالرحیم آبسالان

Department of Medical Laboratory Sciences, Khomein University of Medical Sciences, Markazi Province, Iran

مراجع و منابع این مقاله:

لیست زیر مراجع و منابع استفاده شده در این مقاله را نمایش می دهد. این مراجع به صورت کاملا ماشینی و بر اساس هوش مصنوعی استخراج شده اند و لذا ممکن است دارای اشکالاتی باشند که به مرور زمان دقت استخراج این محتوا افزایش می یابد. مراجعی که مقالات مربوط به آنها در سیویلیکا نمایه شده و پیدا شده اند، به خود مقاله لینک شده اند :
  • Naqvi AAT, Mohammad T, Hasan GM, Hassan MI. Advancements in ...
  • Jafari R, Sadeghi M, Mirzaie M. Investigating the importance of ...
  • MacKerell AD, Bashford D, Bellott M, Dunbrack RL, Evanseck JD, ...
  • Hawkins PC, Skillman AG, Nicholls A. Comparison of shape-matching and ...
  • Pozzan A. Molecular descriptors and methods for ligand based virtual ...
  • Leach AR, Shoichet BK, Peishoff CE. Prediction of protein-ligand interactions. ...
  • Madrid PB, Panchal RG, Warren TK, Shurtleff AC, Endsley AN, ...
  • Mallipeddi PL, Kumar G, White SW, Webb TR. Recent advances ...
  • Savarino A. Expanding the frontiers of existing antiviral drugs: possible ...
  • Jo S, Kim H, Kim S, Shin DH, Kim MS. ...
  • Vankadari N, Wilce JA. Emerging WuHan (COVID-۱۹) coronavirus: glycan shield ...
  • Ton AT, Gentile F, Hsing M, Ban F, Cherkasov A. ...
  • Ekins S, Mottin M, Ramos P, Sousa BKP, Neves BJ, ...
  • Irwin JJ, Sterling T, Mysinger MM, Bolstad ES, Coleman RG. ...
  • Liu X, Zhang B, Jin Z, Yang H, Rao Z. ...
  • Daina A, Michielin O, Zoete V. iLOGP: a simple, robust, ...
  • Daina A, Zoete V. A BOILED-Egg To Predict Gastrointestinal Absorption ...
  • Daina A, Michielin O, Zoete V. SwissADME: a free web ...
  • Gfeller D, Michielin O, Zoete V. Shaping the interaction landscape ...
  • Cramer G, Ford R, Hall R. Estimation of toxic hazard—a ...
  • Munro IC, Ford RA, Kennepohl E, Sprenger JG. Correlation of ...
  • Patlewicz G, Jeliazkova N, Safford RJ, Worth AP, Aleksiev B. ...
  • Daina A, Michielin O, Zoete V. SwissTargetPrediction: updated data and ...
  • Çiçek İ, Tunç T, Ogutcu H, Abdurrahmanoglu S, Günel A, ...
  • Lipinski CA. Avoiding investment in doomed drugs. Curr Drug Discov, ...
  • Hsieh M, Conti M. G-protein-coupled receptor signaling and the EGF ...
  • Friesen JA, Rodwell VW. The ۳-hydroxy-۳-methylglutaryl coenzyme-A (HMG-CoA) reductases. Genome ...
  • Madaan T, Akhtar M, Najmi AK. Sodium glucose CoTransporter ۲ ...
  • WHO. Laboratory biosafety manual. Geneva: World Health Organization ۲۰۰۴ ...
  • WHO. Laboratory testing strategy recommendations for COVID-۱۹: interim guidance, ۲۲ ...
  • Trivella JP, Gutierrez J, Martin P. Dasabuvir : a new ...
  • Sayin M, Gurgen GS, Sayin SS, Guvenc G, Yuceer N. ...
  • Fard JK, Hamzeiy H, Sattari M, Eftekhari A, Ahmadian E, ...
  • Seman L, Macha S, Nehmiz G, Simons G, Ren B, ...
  • Kohler S, Salsali A, Hantel S, Kaspers S, Woerle HJ, ...
  • Riser Taylor S, Harris KB. The clinical efficacy and safety ...
  • Patel P, Louie S. Drug Interactions in HIV: Protease and ...
  • Shen J, Serby M, Reed A, Lee AJ, Menon R, ...
  • Ford N, Vitoria M, Rangaraj A, Norris SL, Calmy A, ...
  • Ke YY, Peng TT, Yeh TK, Huang WZ, Chang SE, ...
  • Jimeno C, Anonuevo-Cruz MC, Uy AB, Bacena AO, Francisco MD, ...
  • Reiner Ž, Hatamipour M, Banach M, Pirro M, Al-Rasadi K, ...
  • Dashti-Khavidaki S, Khalili H. Considerations for Statin Therapy in Patients ...
  • El Kassas M, Elbaz T, Hafez E, Wifi MN, Esmat ...
  • Bidell MR, McLaughlin M, Faragon J, Morse C, Patel N. ...
  • Dimmock NJ, Easton AJ, Leppard KN. Introduction to modern virology. ...
  • نمایش کامل مراجع